Wegovy (semaglutide) is a once-weekly subcutaneous injection licensed in the UK for weight management in adults with obesity or overweight with weight-related comorbidities. Many patients wonder whether injecting Wegovy in the thigh versus the stomach affects treatment outcomes. Both sites are equally approved and effective for this GLP-1 receptor agonist, which regulates appetite and food intake. Understanding the practical differences between these injection locations—including comfort, accessibility, and proper technique—helps patients optimise their treatment experience whilst maintaining the essential practice of regular site rotation to minimise injection site reactions.
Quick Answer: Wegovy demonstrates similar absorption and effectiveness whether injected subcutaneously into the thigh or stomach, with site selection based on individual comfort and body composition.
Wegovy (semaglutide) is a once-weekly subcutaneous injection licensed in the UK for weight management in adults with obesity or overweight with weight-related comorbidities. The medication follows a dose escalation schedule, starting at a lower dose and gradually increasing to the maintenance dose of 2.4 mg. As a glucagon-like peptide-1 (GLP-1) receptor agonist, Wegovy works by mimicking the action of the naturally occurring hormone GLP-1, which regulates appetite and food intake. The medication is administered via a pre-filled, single-dose pen designed for patient self-administration, making proper injection technique essential for treatment success.
According to the Wegovy Summary of Product Characteristics (SmPC), the medication is approved for use in three specific subcutaneous injection sites: the abdomen (stomach area), the thigh (front of the upper leg), and the upper arm. Each of these sites contains adequate subcutaneous tissue—the layer of fat beneath the skin—which allows for proper absorption of the medication into the bloodstream. Understanding the characteristics of different injection sites helps patients make informed decisions about their treatment routine.
Many patients wonder whether the choice between thigh and stomach injections affects the medication's effectiveness or causes different side effects. Whilst both sites are equally approved and effective, individual factors such as comfort, convenience, body composition, and personal preference may influence which site works best for each person. Rotating injection sites is recommended in the SmPC to reduce the risk of injection site reactions. This article examines the practical considerations, technique, and evidence surrounding thigh versus stomach injections for Wegovy, providing guidance to help patients optimise their treatment experience.
Both the thigh and stomach are approved subcutaneous injection sites for Wegovy, and according to the European Medicines Agency's European Public Assessment Report (EPAR), the medication demonstrates similar exposure regardless of which approved site is used. The abdomen (avoiding the navel area) is often considered the most convenient site for many patients, as it typically has a generous layer of subcutaneous fat and is easily accessible. The stomach area generally allows for a comfortable pinch of skin, making it straightforward to ensure the injection reaches the subcutaneous layer rather than muscle tissue.
The thigh—specifically the front and outer portions of the upper leg, midway between the hip and knee—offers an alternative that some patients prefer. This site may be particularly suitable for individuals who have less subcutaneous fat in the abdominal area, those who find the stomach uncomfortable due to clothing waistbands, or patients who simply prefer the accessibility of the thigh. The thigh can be especially convenient for patients who have difficulty reaching their abdomen or who experience tenderness in that area.
Key differences between these sites are largely practical rather than pharmacological:
Accessibility: The stomach is typically easier to see and reach for most people, whilst the thigh may be more accessible for those with limited flexibility or abdominal sensitivity
Subcutaneous fat distribution: Individual body composition varies; some people have more subcutaneous tissue in the abdomen, others in the thighs
Comfort and sensitivity: Personal pain tolerance and skin sensitivity differ between body areas
Lifestyle factors: Clothing, physical activity, and daily routines may make one site more practical than another
It's worth noting that while the upper arm is also an approved injection site, many patients find this location difficult to self-administer and may require assistance from another person.
No clinically meaningful differences in efficacy or side effects have been reported between injection sites. The most important consideration is proper injection technique and consistent site rotation to maintain treatment efficacy and minimise local reactions.
Mounjaro® is the most innovative GLP-1 medication proven to dramatically curb appetite, hunger, and cravings to help professional men achieve substantial weight loss.
Start Here
Wegovy® is a weekly injectable GLP-1 medication with proven effectiveness in reducing appetite, hunger, and cravings to help busy professionals lose significant weight.
Start HereAdministering Wegovy in the thigh requires proper technique to ensure the medication reaches the subcutaneous tissue and to minimise discomfort or complications. The recommended injection area is the front and outer portion of the thigh, approximately midway between the hip and knee. The inner thigh is not recommended as an injection site.
Step-by-step injection technique for the thigh according to the Wegovy Patient Information Leaflet (PIL):
Prepare the injection: Remove Wegovy from the refrigerator and allow it to reach room temperature as per the PIL instructions. Check the medication is clear and colourless. Wash your hands thoroughly with soap and water.
Select and prepare the site: Choose a spot on the front or outer thigh that has not been used recently (rotate sites weekly). Clean the area with an alcohol wipe and allow it to dry completely—injecting into wet skin can cause stinging.
Prepare for injection: For patients with less subcutaneous tissue, gently pinch the skin at the injection site. This helps ensure the medication is delivered to the subcutaneous layer rather than muscle tissue. For many patients, pinching is optional.
Administer the injection: Hold the pen at a 90-degree angle to the skin. Press the pen firmly against the skin until you hear a click, then hold the pen in place until the yellow bar in the indicator window has stopped moving and you have counted to 10, as directed in the PIL.
Complete the injection: Remove the pen from your skin. A small amount of bleeding or bruising is normal. Do not rub the injection site, as this may affect absorption.
Important safety considerations:
Never inject Wegovy intramuscularly or intravenously; it must be administered subcutaneously only
Never share your Wegovy pen with another person, even if the needle is changed
Do not inject through clothing
If you experience persistent pain, significant bruising, or signs of infection (redness, warmth, swelling), contact your GP or prescribing clinician
Never inject into areas with skin changes, bruises, or scarring
Proper disposal of used pens in a sharps container is essential for safety. Obtain a sharps bin from your GP or pharmacy, and return it when full via your local community pharmacy or Local Authority collection service. Never dispose of used pens in household waste.
A common concern amongst patients is whether the injection site affects how well Wegovy works or how quickly it is absorbed into the bloodstream. According to the Wegovy SmPC and EMA EPAR, subcutaneous semaglutide demonstrates similar exposure across approved injection sites, meaning the medication is absorbed and utilised by the body in a comparable manner whether injected into the thigh, abdomen, or upper arm.
Semaglutide's mechanism of action—activating GLP-1 receptors in the brain, pancreas, and gastrointestinal tract—depends on the medication reaching systemic circulation, not on the specific injection location. Once absorbed from subcutaneous tissue, semaglutide enters the bloodstream and exerts its effects throughout the body. The medication has a long half-life of approximately one week, which contributes to its once-weekly dosing schedule and helps maintain stable blood levels regardless of minor variations in absorption rate between sites.
Some theoretical considerations regarding absorption include:
Blood flow: Areas with slightly higher blood flow may show marginally faster absorption, but this difference is not clinically significant for a long-acting medication like semaglutide
Subcutaneous tissue depth: Adequate fat tissue at any approved site ensures proper absorption; very lean individuals should discuss optimal sites with their healthcare provider
Physical activity: There is no official evidence that exercise after injection affects treatment outcomes with Wegovy
It is important to emphasise that Wegovy must be administered subcutaneously only, never intravenously or intramuscularly.
Clinical trials supporting Wegovy's efficacy did not demonstrate meaningful differences in weight loss outcomes based on injection site. The STEP (Semaglutide Treatment Effect in People with obesity) clinical trial programme, which established Wegovy's effectiveness, allowed participants to use any approved injection site. What matters most for treatment success is consistent weekly administration, proper dose escalation, and adherence to lifestyle modifications including diet and physical activity, rather than the specific anatomical location chosen for injection.
Selecting between thigh and stomach injections for Wegovy is ultimately a personal decision based on individual circumstances, comfort, and practical considerations. Both sites are equally effective when proper injection technique is used, so the choice should prioritise what works best for your body and lifestyle whilst maintaining the essential practice of regular site rotation.
Factors to consider when choosing your injection site:
Body composition: Assess where you have adequate subcutaneous fat. Pinch the skin at potential sites—you should be able to grasp enough tissue comfortably. Those with less abdominal fat may find the thigh more suitable, and vice versa.
Comfort and sensitivity: Some individuals find the stomach more sensitive, particularly around the navel area or along previous surgical scars. Others may experience more discomfort in the thigh. Experiment with both sites to determine your preference.
Accessibility and visibility: Consider which site you can reach easily and see clearly. Good visibility helps ensure proper technique and allows you to inspect the area for any reactions. Note that upper arm injections typically require assistance from another person.
Daily activities: If you wear tight waistbands or belts, stomach injections might cause irritation. Similarly, if you engage in activities involving thigh pressure (such as cycling), you might prefer abdominal injections on those days.
Existing skin conditions: Avoid areas with eczema, psoriasis, scarring, or other skin changes. Choose the site with healthier skin.
The importance of site rotation cannot be overstated. As recommended in the Wegovy PIL, rotate within and between approved regions, avoiding using the exact same spot consecutively. This practice reduces injection site reactions and maintains consistent absorption.
If you experience persistent difficulties with injection technique, repeated injection site reactions, or uncertainty about proper administration, contact your prescribing clinician, practice nurse, or community pharmacist. Many NHS services, including community pharmacies and specialist weight management clinics under NICE TA875 guidance, offer injection training and ongoing support. Remember that Wegovy is most effective when combined with a reduced-calorie diet and increased physical activity, as recommended by NICE guidance for weight management interventions.
Wegovy demonstrates similar absorption and effectiveness in both the thigh and stomach. Clinical evidence shows no meaningful difference in weight loss outcomes between approved injection sites when proper subcutaneous technique is used.
Inject Wegovy into the front or outer portion of the thigh, midway between hip and knee. Clean the area, hold the pen at 90 degrees to the skin, press firmly until you hear a click, then hold for 10 seconds as the yellow bar stops moving.
Yes, regular site rotation between and within approved regions (abdomen, thigh, upper arm) is recommended to reduce injection site reactions and maintain consistent medication absorption. Avoid using the exact same spot consecutively.
All medical content on this blog is created based on reputable, evidence-based sources and reviewed regularly for accuracy and relevance. While we strive to keep content up to date with the latest research and clinical guidelines, it is intended for general informational purposes only.
DisclaimerThis content is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional with any medical questions or concerns. Use of the information is at your own risk, and we are not responsible for any consequences resulting from its use.
